Tech Center 1600 • Art Units: 1641 1644 1645 1674
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16817671 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 17542138 | METHOD FOR REGENERATION OF AN OVERLOAD CHROMATOGRAPHY COLUMN | Non-Final OA | Genentech, Inc. |
| 17699868 | METHODS FOR REDUCING TOXICITY OF A CHEMOTHERAPEUTIC DRUG | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17928561 | ANTIBODY FORMULATIONS AND USES THEREOF | Non-Final OA | Amgen Inc. |
| 17281896 | METHODS FOR REDUCING AGGREGATION OF BISPECIFIC ANTIBODIES | Non-Final OA | AMGEN INC. |
| 17628189 | LYOPHILIZED ANTIBODY FORMULATION | Non-Final OA | ICHNOS SCIENCES SA |
| 17335680 | Method for the reduction of host cell proteins in affinity chromatography | Final Rejection | Hoffmann-La Roche Inc. |
| 19248893 | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18620255 | PROCESS FOR PURIFICATION OF FUSION PROTEIN | Non-Final OA | Kashiv BioSciences, LLC |
| 18336889 | COMPOSITIONS COMPRISING AN ANTI-LAG-3 ANTIBODY OR AN ANTI-LAG-3 ANTIBODY AND AN ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY | Non-Final OA | Bristol-Myers Squibb Company |
| 19190045 | RISANKIZUMAB COMPOSITIONS | Non-Final OA | ABBVIE INC. |
| 17417871 | PREPARATION INCLUDING VACCINE ADJUVANT | Final Rejection | Sumitomo Pharma Co., Ltd. |
| 19070188 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SYSTEM ATROPHY (MSA) | Non-Final OA | H. Lundbeck A/S |
| 18176844 | THERAPEUTIC ANTIBODY FORMULATION | Non-Final OA | Eli Lilly and Company |
| 19045166 | STABLE, AQUEOUS FORMULATIONS OF ANTIBODIES THAT BIND IL5 RECEPTOR | Final Rejection | ASTRAZENECA AB |
| 17755801 | TYPE I INTERFERON INHIBITION IN SYSTEMIC LUPUS ERYTHEMATOSUS | Final Rejection | ASTRAZENECA AB |
| 18011412 | TYPE 2 CYTOKINES AS PREDICTORS OF DISEASE SEVERITY AND/OR AS THERAPEUTIC TARGETS FOR COVID-19 | Final Rejection | University of Virginia Patent Foundation |
| 18926209 | METHOD OF TREATING PRECLINICIAL ALZHEIMER'S DISEASE | Final Rejection | AC IMMUNE SA |
| 18907018 | Particle Formation And Morphology | Final Rejection | Elektrofi, Inc. |
| 17292423 | REGULATORY T CELL (TREG) COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | Non-Final OA | THE METHODIST HOSPITAL |
| 16640914 | ANTIBODY-DRUG CONJUGATE PREPARATION AND LYOPHILIZATION FOR SAME | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 15761777 | Method Of Preparing A Therapeutic Protein Formulation And Antibody Formulation Produced By Such A Method | Final Rejection | PFIZER INC. |
| 18152872 | Pharmaceutical Formulations | Non-Final OA | UCB BIOPHARMA SRL |
| 18199675 | FORMULATIONS OF ANTIBODY | Non-Final OA | BIOCON LIMITED |
| 18257600 | CONJUGATED AFLATOXIN B TO PROTECT AGAINST MYCOTOXICOSIS | Non-Final OA | Intervet Inc. |
| 17738131 | HIGH CONCENTRATION ANTI-C5 ANTIBODY FORMULATIONS | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 17914087 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | Final Rejection | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18176155 | HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS | Non-Final OA | Omeros Corporation |
| 16634497 | REAGENTS FOR EXPANDING CELLS EXPRESSING RECOMBINANT RECEPTORS | Non-Final OA | Juno Therapeutics, Inc. |
| 18036546 | STABLE AQUEOUS HIGH CONCENTRATION FORMULATION OF INTEGRIN ANTIBODY | Non-Final OA | DR. REDDY’S LABORATORIES LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy